GO:0006865

BP

amino acid transport

The directed movement of amino acids, organic acids containing one or more amino substituents, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.

SLC3A2, SLC6A6, SLC1A4, SLC7A2, SLC7A9, SLC7A5, SLC1A5, SLC36A1, SLC16A10, SLC38A5, SLC7A6, SLC38A1, SLC7A8, SLC7A7, SLC6A14, SLC7A11

GO:0006867

BP

asparagine transport

The directed movement of asparagine, alpha-aminosuccinamic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.

SLC38A1

GO:0006868

BP

glutamine transport

The directed movement of glutamine, 2-amino-4-carbamoylbutanoic acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.

SLC1A4, SLC1A5, SLC38A1

GO:0006869

BP

lipid transport

The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.

ESYT2, NME4, ABCA8, APOD, SERPINA5, PSAP, GM2A, TSPO, CHKA, VLDLR, HDLBP, APOBR, STARD3, ANO6, APOA5, LRP10, ABCA6, ABCA5, SORL1, SLCO2A1, APOLD1, OSBPL9, SIGMAR1, APOL2, ESYT1, APOO, OSBPL11, OSBPL10, OSBPL1A, OSBPL6, PCTP

GO:0006874

BP

cellular calcium ion homeostasis

Any process involved in the maintenance of an internal steady state of calcium ions at the level of a cell.

STC2, VAPB, TGFB1, PTH, APOE, ATP1B1, PRKCB, CCL3, VDR, CCL2, CCL5, TPT1, TNNI3, ATP2B1, ATP2B4, CALR, HTR2C, CHRNA7, HTR2B, PIK3CB, CXCL12, STC1, CCL8, ATP2C1, ANK2, CAV1, DMPK, RGN, ATP13A5, SYPL2, SV2A, CHERP, TPCN2, RYR2, TMEM203, ATP13A3, TRPV4, TMEM165, SLC24A3, ATP13A2, STIM2, SLC30A1

GO:0006875

BP

cellular metal ion homeostasis

Any process involved in the maintenance of an internal steady state of metal ions at the level of a cell.

LETM1, MT3, LETM2

GO:0006876

BP

cellular cadmium ion homeostasis

Any process involved in the maintenance of an internal steady state of cadmium ions at the level of a cell.

SLC11A1

GO:0006878

BP

cellular copper ion homeostasis

Any process involved in the maintenance of an internal steady state of copper ions at the level of a cell.

ATOX1, SLC31A1, SLC31A2, MT2A, PRNP, APP, ARF1, PRND

GO:0006879

BP

cellular iron ion homeostasis

Any process involved in the maintenance of an internal steady state of iron ions at the level of a cell.

MYC, TFRC, TF, FTL, FTH1, HMOX1, BMP6, SLC11A1, SLC11A2, LCN2, HAMP, SMAD4, FXN, HIF1A, HFE, CYBRD1, TMPRSS6, SLC46A1, HEPH, NDFIP1, ABCB6, SLC40A1, ATP13A2, TFR2

GO:0006880

BP

intracellular sequestering of iron ion

The process of binding or confining iron ions in an intracellular area such that they are separated from other components of a biological system.

FTL, FTH1, SRI

GO:0006882

BP

cellular zinc ion homeostasis

Any process involved in the maintenance of an internal steady state of zinc ions at the level of a cell.

MT3, MT1X, SLC39A6, SLC39A14, SLC39A4, SLC30A8, SLC39A8, ATP13A2, SLC39A10, SLC30A1

GO:0006883

BP

cellular sodium ion homeostasis

Any process involved in the maintenance of an internal steady state of sodium ions at the level of a cell.

AGT, ATP1B1, AGTR2, ATP1A2, ATP12A, ATP1B3, SGK3, NEDD4L

GO:0006884

BP

cell volume homeostasis

Any process involved in maintaining the steady state of a cell's volume. The cell's volume refers to the three-dimensional space occupied by a cell.

CLCN6, LRRC8A, TRPV4

GO:0006885

BP

regulation of pH

Any process involved in the maintenance of an internal equilibrium of hydrogen ions, thereby modulating the internal pH, within an organism or cell.

EDN1, CLCN3, ATP12A, PDK4

GO:0006886

BP

intracellular protein transport

The directed movement of proteins in a cell, including the movement of proteins between specific compartments or structures within a cell, such as organelles of a eukaryotic cell.

AP3D1, DSCR3, STX7, STX6, TBC1D4, TBC1D12, RAMP1, RAMP3, PDCD6, VPS26A, STX11, AP1G2, STAM2, SEC24D, AP2A2, SNAPIN, TBC1D8, CD74, SCG5, NPM1, NGFR, CLTA, TBC1D3H, ZP3, KDELR1, CHML, ERP29, STX2, NSF, ARCN1, TMED10, BCAP31, ARFIP1, COPA, AP3M2, AP2S1, SEC13, AP1S2, AP3S2, COPZ1, AP1S1, RHOB, AP2B1, CDK5, APBA1, YWHAH, TBC1D8B, AP1B1, STX4, STX3, SNX1, CTTN, TMED2, SEC23A, RABGAP1L, WLS, GRTP1, TBC1D9B, TBC1D3C, TBC1D9, HID1, TBC1D3, EXPH5, MYRIP, TBC1D16, TBC1D15, SYTL5, SNX33, TBC1D5, APPBP2, USP6NL, STAM, RPGR, ARHGEF2, ACD, SYTL4, RUNDC1, EVI5L, AP2M1, VPS35, SNX18, MLPH, IFT27, ASPSCR1, NAPB, RAB3GAP2, SYTL2, ARFGAP3, SNX15, TBC1D14, HDAC6, VPS29, GGA2, GGA1, TLK1, ANKRD50, MYO6, SYNRG, RPH3AL, SNX6, TBC1D2B, RIMS2, RABGAP1, SNX9, SNX5, COPG1, SAR1B

GO:0006887

BP

exocytosis

A process of secretion by a cell that results in the release of intracellular molecules (e.g. hormones, matrix proteins) contained within a membrane-bounded vesicle by fusion of the vesicle with the plasma membrane of a cell. This process begins with steps that prepare vesicles for fusion with the membrane (tethering and docking) and ends when vesicle fusion is complete. This is the process in which most molecules are secreted from eukaryotic cells.

WASH1, MYO1G, PIK3C2A, EXOC5, SCAMP1, EXOC3, VAMP4, SNAP29, CCL3, RALA, CCL5, NSF, RAB27A, PRSS12, VAMP2, CCL8, CDK16, TNFAIP2, VAMP3, PDZD11, STXBP5, SNX19, VMP1, LIN7B, SYTL2, LIN7C, EXOC1, RPH3AL, EXOC7, STXBP5L, MYO5A, ARFGEF2

GO:0006888

BP

ER to Golgi vesicle-mediated transport

The directed movement of substances from the endoplasmic reticulum (ER) to the Golgi, mediated by COP II vesicles. Small COP II coated vesicles form from the ER and then fuse directly with the cis-Golgi. Larger structures are transported along microtubules to the cis-Golgi.

DCTN6, DYNC1I1, COPE, GOSR2, DYNC1LI2, SEC22B, SEC24D, SEC31A, VAPB, F8, F2, SERPINA1, TGFA, INS, BGLAP, CD55, TRAPPC2, F5, FOLR1, AREG, ARF4, KDELR1, NSF, ARCN1, TMED10, BCAP31, VAMP7, COPA, CTSC, VCP, COPZ1, RAB1A, DYNLL1, SPTBN1, ANK2, GOLGA2, ANK3, DYNC1I2, DCTN2, CUL3, DCTN1, DYNC1H1, GAS6, COG2, TMED2, SEC23A, KLHL12, TEX261, ARFGAP2, MCFD2, DYNC2LI1, GBF1, ERGIC1, SEC22A, LMF1, DCTN5, RAB1B, LMAN2L, SPTBN4, GOPC, RANGRF, ARFGAP3, NRBP2, BET1L, VAPA, SPAST, CTSZ, VTI1B, COG6, TMED3, HYOU1, TRAPPC1, IER3IP1, COPG1, SAR1B

GO:0006890

BP

retrograde vesicle-mediated transport, Golgi to ER

The directed movement of substances from the Golgi back to the endoplasmic reticulum, mediated by vesicles bearing specific protein coats such as COPI or COG.

COPE, SURF4, KDELR3, KIF1C, ATP9A, SEC22B, KIF4A, ARF4, KDELR1, HTT, NSF, ARCN1, PITPNB, TMED10, KIF11, COPA, COPZ1, RAB1A, ARF5, CENPE, KIF23, KIF22, TMED2, ARFGAP2, KIF18A, GBF1, KIFAP3, SCYL1, ERGIC2, KIF2C, RACGAP1, RAB1B, ARFGAP3, RAB6B, KIF15, TMED3, KIF3A, COPG1

GO:0006891

BP

intra-Golgi vesicle-mediated transport

The directed movement of substances within the Golgi, mediated by small transport vesicles. These either fuse with the cis-Golgi or with each other to form the membrane stacks known as the cis-Golgi reticulum (network).

COPE, GOSR2, NSF, TRAPPC10, COPA, GABARAPL2, COPZ1, COG2, RAB6B, VTI1B, COG6

GO:0006892

BP

post-Golgi vesicle-mediated transport

The directed movement of substances from the Golgi to other parts of the cell, including organelles and the plasma membrane, mediated by small transport vesicles.

SNAP23, EXOC5, SCAMP1, SCAMP2, RP2, VAMP7, VAMP2, ARF1, STX4, GBF1, SORL1, MYO5A

GO:0006893

BP

Golgi to plasma membrane transport

The directed movement of substances from the Golgi to the plasma membrane in transport vesicles that move from the trans-Golgi network to the plasma membrane, where they fuse and release their contents by exocytosis.

CCDC93, COMMD1, STXBP6, EXOC2, GOPC, EXOC1, ARFGEF2

GO:0006895

BP

Golgi to endosome transport

The directed movement of substances from the Golgi to early sorting endosomes. Clathrin vesicles transport substances from the trans-Golgi to endosomes.

RAB29, EPS15, VPS13C, MON2, GBF1

GO:0006896

BP

Golgi to vacuole transport

The directed movement of substances from the Golgi to the vacuole.

GOSR2, VTI1B

GO:0006897

BP

endocytosis

A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.

ESYT2, WIPF3, PIK3C2A, BIN1, NPC1, LY75, ATP9A, LRP5, SNX4, LDLR, APP, GHR, NME1, RAB5A, CHRNA7, CSNK1D, PIK3CG, CSNK1E, TSC2, RAB7A, VAMP7, RAB1A, LRP2, TNK2, MYO1E, UNC119, EEA1, RABEP1, RALBP1, TRIP10, DPYSL2, AAK1, ARC, MIB1, NOSTRIN, DNER, RIN3, DENND1A, SNX33, STAB2, RIN2, HOOK2, C9orf72, SNX18, FNBP1, SIGLEC1, CSNK1G1, CD209, ITSN2, SH3BP4, ANKFY1, ATP6V1H, RABGEF1, RAB22A, MYO6, SYNRG, SNX6, USP20, SNX9, CSNK1G3, STON1

GO:0006898

BP

receptor-mediated endocytosis

An endocytosis process in which cell surface receptors ensure specificity of transport. A specific receptor on the cell surface binds tightly to the extracellular macromolecule (the ligand) that it recognizes; the plasma-membrane region containing the receptor-ligand complex then undergoes endocytosis, forming a transport vesicle containing the receptor-ligand complex and excluding most other plasma-membrane proteins. Receptor-mediated endocytosis generally occurs via clathrin-coated pits and vesicles.

ENPP3, CD5L, HP, LDLR, APOA1, APOE, AMBP, ALB, VTN, APOB, CFI, ADRB2, HSP90AA1, CD14, SPARC, SAA1, IGF2R, FCGR1A, HSP90B1, FOLR1, CD36, ENPP1, MRC1, CALR, CD6, LRPAP1, TGFBR2, PPT1, PRSS12, AP1S1, HBB, HBA1, OLR1, DAB2, VLDLR, LRP2, APOBR, CLN3, PICALM, ENPP2, SCARF1, CTTN, COLEC12, LDLRAP1, LRP10, RABEPK, CD163, SBSPON, SCARB1, STAB2, HSPH1, FCGR1B, SORL1, PRG4, LOXL4, TINAGL1, CXCL16, ACKR4, PDLIM7, CD163L1, STAB1, PI4KB, DMBT1, TFR2, LOXL2, HYOU1, SNX9

GO:0006900

BP

membrane budding

The evagination of a membrane, resulting in formation of a vesicle.

WASL, ANXA2, S100A10, FNBP1L

GO:0006903

BP

vesicle targeting

The process in which vesicles are directed to specific destination membranes. Targeting involves coordinated interactions among cytoskeletal elements (microtubules or actin filaments), motor proteins, molecules at the vesicle membrane and target membrane surfaces, and vesicle cargo.

SNAP23, SNAP29, LRMP

GO:0006904

BP

vesicle docking involved in exocytosis

The initial attachment of a vesicle membrane to a target membrane, mediated by proteins protruding from the membrane of the vesicle and the target membrane, that contributes to exocytosis.

CFTR, STXBP1, STXBP2, VAMP3, CPLX2, RABEPK, SCFD2, RAB8B, EXOC4, SYTL2, VTI1B

GO:0006906

BP

vesicle fusion

Fusion of the membrane of a transport vesicle with its target membrane.

STX7, STX6, GNAI3, SYT1, CAV2, VAMP7, VAMP2, LRMP, EEA1, VAMP3, C2CD5, SYTL5, SYTL4, SYT11, SYTL2, VAV3, RPH3AL

GO:0006907

BP

pinocytosis

An endocytosis process that results in the uptake of liquid material by cells from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, called pinosomes, formed by invagination of the plasma membrane.

AHSG, PPT1, EHD4, SNX5

GO:0006909

BP

phagocytosis

An endocytosis process that results in the engulfment of external particulate material by phagocytes. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles.

CDC7, PIP5K1C, CEACAM4, TUSC2, ANXA1, ITGB2, CD14, ANXA3, PECAM1, RAB5A, ADORA1, CORO1A, LEP, LEPR, CSNK1A1, SLC11A1, ANXA11, MERTK, GAS6, CD302, CD93, CDC42SE2, CDC42SE1, CORO1C

GO:0006910

BP

phagocytosis, recognition

The initial step in phagocytosis involving adhesion to bacteria, immune complexes and other particulate matter, or an apoptotic cell and based on recognition of factors such as bacterial cell wall components, opsonins like complement and antibody or protein receptors and lipids like phosphatidyl serine, and leading to intracellular signaling in the phagocytosing cell.

IGLL5, CD36, MFGE8, COLEC12, CLEC7A

GO:0006911

BP

phagocytosis, engulfment

The internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis, including the membrane and cytoskeletal processes required, which involves one of three mechanisms: zippering of pseudopods around a target via repeated receptor-ligand interactions, sinking of the target directly into plasma membrane of the phagocytosing cell, or induced uptake via an enhanced membrane ruffling of the phagocytosing cell similar to macropinocytosis.

IGLL5, ABCA1, FCGR1A, MYH9, VAMP7, MFGE8, ELMO1, BIN2

GO:0006913

BP

nucleocytoplasmic transport

The directed movement of molecules between the nucleus and the cytoplasm.

NPM1, ANP32A, EIF5A, CDK5, SET, CAMK1, FBXO22, NUP205, RSRC1, CITED1, MYBBP1A, ANP32E, UPF3A

GO:0006914

BP

autophagy

The process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation.

VPS37C, TECPR2, NPC1, CHMP2A, VPS4B, STAM2, S100A8, S100A9, CTSD, HMGB1, LAMP1, ARSB, ITGB4, XBP1, TFEB, PIK3CB, DAP, VCP, SESN2, GABARAPL2, RAB1A, FOXO1, SQSTM1, STK11, IFI16, WIPI1, FNBP1L, RAB12, DRAM2, TECPR1, SIRT2, DRAM1, PIK3C3, VPS37A, RB1CC1, TBC1D5, STAM, USP13, MVB12A, NRBF2, VMP1, C9orf72, TMEM59, TOLLIP, RAB1B, ATG10, CHMP4B, VTA1, UBQLN4, PTPN22, SH3GLB1, WDR45

GO:0006915

BP

apoptotic process

A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died.

APBB1, HIP1, EBAG9, MAP2K7, PDCD5, PLSCR1, AXIN1, OGT, BIRC5, TOX3, CFLAR, SIAH2, DAPK3, MAP3K7, RIPK2, BCL2L11, BUB1, TRIAP1, CD5L, RAD21, OPA1, KIF1B, GREM1, BUB1B, TLR2, JAK2, GADD45B, NME6, TNFRSF21, PPP1R15A, PSMD10, STK17B, MFN2, UNC5C, GADD45G, AIFM1, CST3, IL1A, IL1B, RAF1, NR3C1, ITGB2, S100A8, PRKCB, CDK1, S100A9, CD14, LGALS1, PAEP, CTSH, BCL2, IRF1, IAPP, RALB, GJA1, IGFBP3, ERCC2, NFKB1, CAPN3, CDK11B, MAL, TNFAIP3, C5AR1, FGFR2, GADD45A, FAS, MT3, MAPK3, MAPK1, CASP1, PPP2R1A, TSPO, TIA1, AKT2, GRK5, ADRA1A, AHR, CHI3L1, TGFBR1, LTBR, TGFBR2, SNCA, BRCA1, MAP3K8, HTT, IER3, LGALS7, CASP4, COMP, SERPINB9, TNFSF10, FXR1, DAP, MAP2K6, RBM5, DAPK1, CTSC, YARS, CSE1L, CASP9, CASP6, PTEN, CXCR4, UBE2D3, PSME3, DAD1, POLR2G, RHOB, DYNLL1, EIF5A, RACK1, ACTC1, LCN2, DAB2, XIAP, MEF2A, PPARD, NOTCH2, ZBTB16, PRKCD, MEF2C, C1QBP, ZFP36L1, BAX, PPID, EP300, FOXO1, BNIP3, TIAM1, STK4, TRAF1, FADD, PAK2, ITGB3BP, BIRC3, SQSTM1, RIPK1, PMAIP1, C1D, GAS6, SEMA3A, ESPL1, MELK, CASP8, MEF2D, ARL6IP1, PEA15, PRKD1, RABEP1, DHCR24, RPS6KA1, SHB, TRADD, PDCD2, PKN2, MAPK14, PDCD4, PHLDA2, C3orf38, SFRP5, BCL2L15, STPG1, KANK2, ZFAND6, XAF1, JADE1, TCTN3, BRAT1, DRAM2, ADAMTSL4, RASSF6, RNF144B, C6orf120, PEG10, TAX1BP1, SGMS1, TRIM69, C19orf68, RNF130, TMEM219, SIAH1, SULF1, CCAR1, MRPL41, DDIAS, UNC5B, DRAM1, RNF152, PCSK9, RHBDD1, PPP1R13L, PDCD6IP, PRUNE2, PHLDA1, CKAP2, RASSF5, SLC5A11, CSRNP3, RFFL, ELMO1, INPP5D, BAD, TNFRSF25, RFK, MYDGF, TP53INP1, CYFIP2, PAWR, ITCH, CLPTM1L, NOX5, GSDMA, DLC1, CSRNP1, LITAF, CIB1, CITED1, HTATIP2, CDCA7, HINT2, BBC3, BEX2, CADM1, PEG3, CSRNP2, SEMA6A, PDCL3, GHITM, EGLN3, SUDS3, UBE2Z, AKTIP, BCL2L12, RRAGC, NEK6, TRIM39, SRA1, NGB, RTN4, DUSP22, GLRX2, TNFRSF19, RNF216, SLTM, BCLAF1, PAK7, SAP30BP, LGALS13, PUF60, FEM1B, FBXO10, TAOK2, TPX2, PYCARD, PLAGL1, BOK, FAF1, TRIM35, CDK11A, PRELID1, NISCH, EPB41L3, HIF3A, SH3GLB1, NOC2L

GO:0006919

BP

activation of cysteine-type endopeptidase activity involved in apoptotic process

Any process that initiates the activity of the inactive enzyme cysteine-type endopeptidase in the context of an apoptotic process.

HIP1, JAK2, PDCD6, AIFM1, NGF, TNF, S100A8, CCK, S100A9, NGFR, CTSH, HSPD1, F2R, FAS, CASP1, PPARG, SNCA, IFI27, CDKN1B, XDH, TNFSF10, DAP, VCP, BID, HSPE1, RACK1, CRADD, SMAD3, COL4A3, BAX, FADD, RIPK1, PMAIP1, CASP8, TRADD, PDCD2, RPS27L, ANP32B, BAD, FAM162A, DLC1, EGLN3, PYCARD, BOK

GO:0006921

BP

cellular component disassembly involved in execution phase of apoptosis

The breakdown of structures such as organelles, proteins, or other macromolecular structures during apoptosis.

APC, BCAP31, CASP6, SATB1, PRKCQ, PTK2, PRKCD, CASP8, CAPN10, STK24

GO:0006924

BP

activation-induced cell death of T cells

A T cell apoptotic process that occurs towards the end of the expansion phase following the initial activation of mature T cells by antigen and is triggered by T cell receptor stimulation and signals transmitted via various surface-expressed members of the TNF receptor family such as Fas ligand, Fas, and TNF and the p55 and p75 TNF receptors.

FAS, AKT1, RPS6

GO:0006925

BP

inflammatory cell apoptotic process

Any apoptotic process in an inflammatory cell, any cell participating in the inflammatory response to a foreign substance e.g. neutrophil, macrophage.

FAS

GO:0006928

BP

movement of cell or subcellular component

The directed, self-propelled movement of a cell or subcellular component without the involvement of an external agent such as a transporter or a pore.

WASL, DNALI1, ARPC2, ARPC3, SPINT2, MTSS1, JAK2, VNN1, HSPB1, IGF1, TPM3, TUBB, VIM, TPM1, CXCL8, TXN, CCL4, CD9, ANOS1, FPR2, CORO1A, LSP1, PTGS2, SERPINB5, STAT3, CAPZB, CD97, ARHGDIA, ARHGDIB, CAPZA1, ACTB, ACTR3, ACTR2, RAC1, ACTG1, TPM4, TUBB4B, MAP2K1, PLAUR, CALD1, ENPP2, MAPK14, ABI1, CHST4, MYLIP, ELMO1, ABI2, DNAH9, AMFR, TLN1, LYVE1

GO:0006929

BP

substrate-dependent cell migration

The orderly movement of a cell from one site to another along a substrate such as the extracellular matrix; the migrating cell forms a protrusion that attaches to the substrate.

ITGA2, VEGFC, ANKS1A, ITGA11

GO:0006930

BP

substrate-dependent cell migration, cell extension

The formation of a cell surface protrusion, such as a lamellipodium or filopodium, at the leading edge of a migrating cell.

SDCBP, CTTN

GO:0006931

BP

substrate-dependent cell migration, cell attachment to substrate

The formation of adhesions that stabilize protrusions at the leading edge of a migrating cell; involves integrin activation, clustering, and the recruitment of structural and signaling components to nascent adhesions.

TNFRSF12A

GO:0006933

BP

negative regulation of cell adhesion involved in substrate-bound cell migration

The disassembly of adhesions at the front and rear of a migrating cell. At the leading edge, adhesion disassembly accompanies the formation of new protrusions; at the cell rear, it promotes tail retraction.

ITGB1BP1, SNAI2, PTPRC

GO:0006935

BP

chemotaxis

The directed movement of a motile cell or organism, or the directed growth of a cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).

CYR61, CXCL14, PLAU, FGF2, CXCL1, CXCL8, CCL3, RNASE2, RALA, CCL2, CCL5, RAC2, FOSL1, CXCL2, TYMP, S1PR1, FPR1, C5AR1, ANOS1, CXCR2, FPR2, PTAFR, MAPK1, LSP1, PIK3CB, CXCL5, CXCL12, CCL20, CCL8, CXCL6, MAP2K1, PLAUR, PLD1, ENPP2, RALBP1, MAPK14, AMOT, CMTM8, DOCK2, CMTM3, RARRES2, CXCL16, PLGRKT, ACKR4, ZNF580

GO:0006936

BP

muscle contraction

A process in which force is generated within muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis.

FXYD1, SORBS3, NDUFS6, HSBP1, CRYAB, TPM3, TPM2, TPM1, CHRNB1, MYL6B, GJA1, CKMT2, DES, ITGB5, MYL12A, MYL9, TMOD1, LMOD1, OXTR, MYH11, GJC1, SLC6A8, EMD, MYL6, CALM2, ACTA2, ACTG2, TPM4, MYL7, MYL5, CALD1, ASPH, SNTA1, SNTB1, KCNJ12, SSPN, SLMAP, MYLK, PABPN1, TTN, STAC, SORBS1, KCNIP2, MYOT, MYH2, TLN1, MYH4

GO:0006937

BP

regulation of muscle contraction

Any process that modulates the frequency, rate or extent of muscle contraction.

PPP1R12B, ANXA6, TPM1, MYL9, MYL5, KCNA1

GO:0006939

BP

smooth muscle contraction

A process in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Smooth muscle differs from striated muscle in the much higher actin/myosin ratio, the absence of conspicuous sarcomeres and the ability to contract to a much smaller fraction of its resting length.

ROCK2, CHRM3, EDNRA, HTR7, ADRA1A, MYH11, SMTN, PDE4D, MYLK, TPCN2

GO:0006940

BP

regulation of smooth muscle contraction

Any process that modulates the frequency, rate or extent of smooth muscle contraction.

DAPK3, CHRM2, ADRA2B, TNNI3, NMU, ATP1A2, CNN1, CAV1

GO:0006941

BP

striated muscle contraction

A process in which force is generated within striated muscle tissue, resulting in the shortening of the muscle. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Striated muscle is a type of muscle in which the repeating units (sarcomeres) of the contractile myofibrils are arranged in registry throughout the cell, resulting in transverse or oblique striations observable at the level of the light microscope.

ALDOA, TTN, DTNA

GO:0006942

BP

regulation of striated muscle contraction

Any process that modulates the frequency, rate or extent of striated muscle contraction.

SRI, ATP1A2

GO:0006948

BP

induction by virus of host cell-cell fusion

The process of syncytia-forming cell-cell fusion, caused by a virus.

CD4

GO:0006949

BP

syncytium formation

The formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane. Syncytia are normally derived from single cells that fuse or fail to complete cell division.

ERCC1, ERVW-1

GO:0006950

BP

response to stress

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).

MAPK13, GADD45B, GADD45G, EGFR, NPM1, AKR1B1, ATF6, MAPK1, STIP1, EIF1, MAPK8, MAPK9, MAPKAPK2, PRKAA2, SQSTM1, JADE1, MINK1, TP53INP1, SGK3, OMA1, SMG1, PINK1, ZAK, ERRFI1, TAOK2, NDRG4, HILPDA, DUSP10

GO:0006952

BP

defense response

Reactions, triggered in response to the presence of a foreign body or the occurrence of an injury, which result in restriction of damage to the organism attacked or prevention/recovery from the infection caused by the attack.

SOCS6, HP, CST3, CD74, MPO, INHBA, CD48, INHBB, IL32, CRISP3, HSF1, CD83, PSG3, COLEC12, CSF3R, IL17RB

GO:0006953

BP

acute-phase response

An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals.

PLSCR1, F8, F2, HP, ASS1, SERPINA1, SERPINA3, INS, CRP, APCS, FN1, ORM1, AHSG, IL6, IL6R, SAA1, SAA2, MBL2, CEBPB, ORM2, STAT3, HAMP, HFE, SIGIRR, CD163, APOL2, TFR2

GO:0006954

BP

inflammatory response

The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.

TLR4, TNFRSF11B, PIK3CD, TNFRSF10C, TLR3, IRAK2, RIPK2, CD5L, LY75, TPST1, TLR5, TLR2, TSPAN2, SEMA7A, GPR32, TNFRSF21, RPS6KA5, TUSC2, VNN1, SERPINA3, C3, KNG1, FOS, TGFB1, TNF, IL1A, IL1B, CRP, ORM1, PPBP, PF4, ANXA1, CYBB, ITGB2, S100A8, IL6, S100A9, CSF1R, LYN, THBS1, NGFR, CD14, KRT16, CXCL1, HMGB1, C4A, C4B, CXCL8, CCL3, SPP1, KIT, BMP2, CCL4, CCL2, CCL5, SCG2, MIF, ALOX15, SELE, CEBPB, SDC1, NFKB1, CXCL2, TNFRSF1B, FPR1, TNFAIP3, C5AR1, BMP6, IL10, GAL, IGFBP4, PTGS1, SP100, CXCR2, FPR2, PTAFR, F2R, FAS, PTX3, CD27, AOAH, TNFRSF8, CD40LG, ADORA1, AKT1, PTGS2, HRH1, CHI3L1, LTBR, LIPA, BCL6, CXCL5, PTGFR, PTGER3, PTGER2, SYK, CXCL12, PIK3CG, CD97, MAPKAPK2, SLC11A1, CASP4, AGTR2, NDST1, F2RL1, HDAC4, TIRAP, PLP1, CXCR4, LYZ, RAC1, ADAM8, OLR1, ELF3, CCL20, CCL8, CXCL6, TNFAIP6, RELB, RELA, PRKCQ, REL, AOX1, IL10RB, PTGDR, NMI, IL18, NFE2L1, NFATC4, PRKD1, TLR1, SMAD1, SCN9A, IFI16, AOC3, CDO1, THEMIS2, NFRKB, IL34, PXK, CAMK1D, SCUBE1, AFAP1L2, CHST4, ABCF1, BLNK, TNFRSF25, ITCH, NR1H4, S1PR3, GPER1, MGLL, RARRES2, LXN, CLEC7A, NFKBIZ, SIGLEC1, TOLLIP, PLGRKT, MMP25, IL1RAP, NOX4, CYP26B1, STAB1, SPHK1, IL37, TBK1, ZNF580, HDAC9, PYCARD, PLA2G4C, HDAC5, PLAA, CHST2, F11R, TNFRSF11A

GO:0006955

BP

immune response

Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.

TLR4, TNFRSF11B, ENPP3, TNFSF11, TNFRSF10C, FYB, AQP9, SMAD6, LY75, TLR2, FCGR3B, SEMA7A, TNFRSF21, PRKRA, TNFSF13, IKBKAP, CXCL14, PNP, C1R, C3, IL1A, IL1B, CD4, HLA-DRA, HLA-DQA2, HLA-DQA1, HLA-DQB1, PPBP, PF4, FTH1, SLPI, VTN, THBS1, IGF1R, NGFR, CXCL1, CXCL8, FCGR1A, CCL4, PRG2, HLA-DOB, IL1R1, ETS1, LIF, VAV1, CYP11B1, RAG1, CD36, IL7R, CEBPB, XBP1, IL1RN, CXCL2, HLA-DPA1, TNFRSF1B, C5AR1, BMP6, ENPP1, TNFSF4, IL32, IL4R, PTAFR, FAS, CTSS, CD27, CFP, IL1R2, HLA-DMB, TNFRSF8, IL12A, FCGR2B, GPR183, GBP2, PTGER4, BMPR1A, LTBR, ZEB1, CXCL5, NOTCH1, CXCL12, CD97, SERPINB9, TNFSF10, CEBPG, CTSC, GEM, CCL20, CXCL6, HAMP, SMAD3, IFITM3, IL1RL1, TGFBR3, CD164, EXOSC9, C1QBP, IL10RB, ILF2, CHIT1, IL18R1, ENPP2, IL18, NCF4, NECTIN1, TLR1, NFIL3, IRAK1BP1, CD276, OTUD7B, GBP6, PKHD1L1, SBSPON, TRIM22, CHST4, MARCH1, SECTM1, FCGR1B, PRG4, TNFRSF25, MR1, TCF12, SEMA3C, TINAGL1, ACKR4, IL1RAP, IL37, APLN, PRELID1, TNFSF13B, SAMHD1

GO:0006956

BP

complement activation

Any process involved in the activation of any of the steps of the complement cascade, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes; the initial steps of complement activation involve one of three pathways, the classical pathway, the alternative pathway, and the lectin pathway, all of which lead to the terminal complement pathway.

MASP2, C1R, CFB, C3, C1QA, CFH, C1S, C4A, C4B, C7, CLU, MBL2, C6, CFP, CFHR1, FCN2, RGCC

GO:0006957

BP

complement activation, alternative pathway

Any process involved in the activation of any of the steps of the alternative pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes.

CFB, C3, C8G, CFH, C7, CFP, VSIG4

GO:0006958

BP

complement activation, classical pathway

Any process involved in the activation of any of the steps of the classical pathway of the complement cascade which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes.

IGLL5, MASP2, C1R, C3, C1QA, SERPING1, CFI, C8G, CD55, C1S, C4A, C4B, C7, CLU, MBL2, C6, CD46, CR1, C1QBP, SUSD4, C1RL

GO:0006959

BP

humoral immune response

An immune response mediated through a body fluid.

TRAF3IP2, TNFRSF21, TNF, IFNA1 , IFNA16, IL6, GPI, BCL2, CD28, CCL2, ST6GAL1, TFEB, GPR183, PSMB10, NOTCH1, CD83, MEF2C, BST2, IFNE, BLNK, TREM1, YTHDF2

GO:0006968

BP

cellular defense response

A defense response that is mediated by cells.

CD5L, KLRC4, TYROBP, FCMR, BCL10, ITGB1, FOSL1, HLA-G, NCF2, C5AR1, CXCR2, ADORA2B, LSP1, MNDA, KIR3DL2, RELA, TCIRG1, VEZF1, DCDC2, RAB23, ZNF148

GO:0006970

BP

response to osmotic stress

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of solutes outside the organism or cell.

MAP2K7, MAPK13, AQP9, TSC22D2, NFAT5, EGFR, SLC2A1, SORD, KCNMA1, MAP7, LRRC8A, MARVELD3, TSC22D3

GO:0006971

BP

hypotonic response

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hypotonic environment, i.e. an environment with a lower concentration of solutes than the organism or cell.

ITGA2

GO:0006972

BP

hyperosmotic response

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hyperosmotic environment, i.e. an environment with a higher concentration of solutes than the organism or cell.

TLR3, HNMT, SLC12A2, RAC1, PKN1

GO:0006974

BP

cellular response to DNA damage stimulus

Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism.

MACROD2, DDX39A, APBB1, CHD2, CHEK1, NUAK1, RAD1, BRD4, POLQ, PPP1R15A, RNF8, UBR5, MYC, TP53, LYN, PARP1, FBXO45, BCL2, TOP2A, H2AFX, BCL3, UBA1, APC, YY1, MAPK1, AKT1, MCM7, DDIT3, GNL1, BRCA1, CDKN1A, BCL6, MNDA, YAP1, MAPKAPK2, PSEN1, MRE11A, NEK4, BLM, VCP, CASP9, UBE2B, BTG2, XIAP, CDK3, RAD51, FMR1, FOXO1, NFATC2, CUL4A, SPIDR, PSME4, SHPRH, KIAA0101, RBBP5, STK11, MICA, FBXO31, INTS3, NIPBL, FAAP20, BRAT1, RPS27L, MCM10, SETX, RBBP6, CHD1L, SLF2, SMC5, CCAR2, APITD1, ZBTB38, RNF169, BOD1L1, FBXO18, SPATA18, SETD7, SUSD6, TOPBP1, DYRK2, TANK, RAD50, NABP1, OTUB1, MASTL, UBE2E2, USP28, SMC6, RAD9A, BARD1, NPAS2, CIB1, NABP2, MACROD1, SLF1, ALKBH7, WAC, PITHD1, TAOK3, EGLN3, UBE2T, INIP, RAD18, CDKN2AIP, AATF, FMN2, DTL, ZBTB4, ASH2L, BAZ1B, MCM8, TLK1, VAV3, TAOK2, TIMELESS

GO:0006975

BP

DNA damage induced protein phosphorylation

The widespread phosphorylation of various molecules, triggering many downstream processes, that occurs in response to the detection of DNA damage.

CHEK1, MAPK3, MAP2K6, CRY1

GO:0006977

BP

DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest

A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage and resulting in the stopping or reduction in rate of the cell cycle.

CNOT1, AURKA, MDM4, TRIAP1, CNOT3, CNOT4, TP53, CDK1, NPM1, UBC, PCNA, CCNB1, MUC1, GADD45A, CDK2, CDC25C, SFN, CDKN1A, CDKN1B, PCBP4, RPS27A, UBA52, BTG2, CRADD, MDM2, E2F1, SOX4, BAX, EP300, TFDP1, CARM1, ARID3A, PRMT1, RGCC, CENPJ, PLK2, GTSE1, CNOT7, CNOT6, PLAGL1

GO:0006978

BP

DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator

A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, resulting in the induction of the transcription of p21 (also known as WAF1, CIP1 and SDI1) or any equivalent protein, in response to the detection of DNA damage.

TP53, MUC1, SP100, BRCA1, BRCA2, FOXM1, HIPK2

GO:0006979

BP

response to oxidative stress

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.

PDLIM1, NDUFS8, ATOX1, TOR1A, PARK2, NDUFS2, PSIP1, IDH1, STC2, NDUFB4, VNN1, EGFR, PRNP, KRT1, APP, MPO, CA3, ERCC1, HMOX1, MBL2, ALAD, ERCC2, XPA, PTGS1, PSMB5, DUSP1, AKT1, PRDX2, PTGS2, NUDT1, GPX4, GCLC, GCLM, PSEN1, SEPP1, MMP14, BTG1, GAB1, MTF1, DHCR24, ETFDH, MICB, DGKK, MSRB3, OXR1, CYGB, IPCEF1, RBPMS, ALS2, PINK1, DUOX2, DUOX1, SLC23A2, SLC7A11

GO:0006982

BP

response to lipid hydroperoxide

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid hydroperoxide stimulus. Lipid hydroperoxide is the highly reactive primary oxygenated products of polyunsaturated fatty acids.

GPX3

GO:0006983

BP

ER overload response

The series of molecular signals generated by the accumulation of normal or misfolded proteins in the endoplasmic reticulum and leading to activation of transcription by NF-kappaB.

TP53, HSPA5, DDIT3, GSK3B, CCDC47, VIMP, TMCO1

GO:0006984

BP

ER-nucleus signaling pathway

Any series of molecular signals that conveys information from the endoplasmic reticulum to the nucleus, usually resulting in a change in transcriptional regulation.

ATP2A2

GO:0006986

BP

response to unfolded protein

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an unfolded protein stimulus.

TMEM129, MFN2, HSPB1, HSP90AA1, THBS1, HSP90AB1, HSPD1, HSPA6, DNAJB1, DNAJB2, DNAJA1, HSPA1L, HSPA4, THBS4, DDIT3, SERPINH1, HSPE1, HSPB3, HSPB2, CREBRF, UBE2J2, STT3B, HSPH1, FAF2, ERP44, HERPUD2, CHAC1, DNAJC4, JKAMP, DNAJB4

GO:0006987

BP

activation of signaling protein activity involved in unfolded protein response

The conversion of a specific protein, possessing protein kinase and endoribonuclease activities, to an active form as a result of signaling via the unfolded protein response.

ERN1, VAPB, HSPA5, BAX

GO:0006990

BP

positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response

The activation of genes whose promoters contain a specific sequence elements such as the unfolded protein response element (UPRE; consensus CAGCGTG) or the ER stress-response element (ERSE; CCAAN(N)9CCACG), as a result of signaling via the unfolded protein response.

XBP1, ATF6, EP300

GO:0006991

BP

response to sterol depletion

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating deprivation of sterols. Sterols are a group of steroids characterized by the presence of one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.

LYN

GO:0006995

BP

cellular response to nitrogen starvation

Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of nitrogen.

GABARAPL2, RB1CC1, MAP1LC3B, GABARAPL1, MAP1LC3A

GO:0006996

BP

organelle organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an organelle within a cell. An organelle is an organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. Excludes the plasma membrane.

TOR1A, KIF5C, KIF4A, ATP2A2, HPS3, HDAC6, KIF3A

GO:0006997

BP

nucleus organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nucleus.

BIN1, CHMP2A, VPS4B, PITPNB, H3F3A, GOLM1, CHMP4B

GO:0006998

BP

nuclear envelope organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear envelope.

TOR1A, NUP155, CTDNEP1, DMPK, REEP3, NUP93, TMEM170A, SYNE2, SPAG4, PARP11, SUN2

GO:0006999

BP

nuclear pore organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear pore.

TPR, NUP35, SEH1L

GO:0007000

BP

nucleolus organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nucleolus.

RRN3

GO:0007004

BP

telomere maintenance via telomerase

The maintenance of proper telomeric length by the addition of telomeric repeats by telomerase.

DKC1, MRE11A, TERF1, RAD50, ACD, NOP10, POT1, GAR1

GO:0007005

BP

mitochondrion organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components.

FANCG, PARK2, OPA1, PARP1, ESRRA, TMEM11, NOS3, PHB, HMGCL, CAV2, CXADR, CYCS, TFAM, SSBP1, GABPA, RAB32, MTFR1, FXN, MTFR2, VPS13C, PPARGC1B, CHCHD10, MIEF2, SLC25A36, PEO1, CEP89, YME1L1, MTERF1, PHB2, EPAS1, PINK1, SEPN1, PPARGC1A, AGTPBP1, BCS1L, CHCHD2

GO:0007006

BP

mitochondrial membrane organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrial membrane, either of the lipid bilayer surrounding a mitochondrion.

MFN2, SNCA, TIMM50

GO:0007007

BP

inner mitochondrial membrane organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the mitochondrial inner membrane.

OPA1

GO:0007009

BP

plasma membrane organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the plasma membrane.

MTSS1, CRB1, SPTBN1, ANK3, BAIAP2L1

GO:0007010

BP

cytoskeleton organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures.

HIP1, ABLIM1, C21orf2, PPL, OBSL1, PRPF40A, RP2, MICAL2, YEATS4, ZMYM6, APOE, TUBB4A, KRT16, TPM1, CCL3, DMD, CCL2, KRT13, DES, CFL1, CTNNA2, PRKCI, CAPZB, SOX9, ACTB, TUBA4A, TUBB4B, SPTBN1, ANK2, DST, TUBB3, TUBA3C, TUBB2A, ZMYM3, NEDD9, KISS1, CCDC6, DPYSL2, QRICH1, CAMSAP1, MAST2, BRWD3, FGD6, LARP4, TUBA1A, RHOU, MAEA, ARC, FGD2, PDZD8, MICAL1, ARAP3, PHIP, PALLD, AJUBA, FGD4, FMNL2, TUBB6, TUBB2B, SEMA6A, PSTPIP2, BRWD1, TBCCD1, ABI2, ZAK, MARK1, PAK7, ZMYM2, ADD3, ZRANB1, LIMD1, TUBD1, TNIK, CDC42BPB, PCLO

GO:0007015

BP

actin filament organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments. Includes processes that control the spatial distribution of actin filaments, such as organizing filaments into meshworks, bundles, or other structures, as by cross-linking.

SORBS3, DIAPH2, SORBS2, ALDOA, TMSB15A, BCL2, ACTN1, RAC2, TMOD1, LMOD1, CORO1A, CTNNA1, PRKCI, EMP2, TMSB4X, TMSB10, ARF1, DLG1, FAT1, DBN1, LRRC16A, RUFY3, PPARGC1B, ARHGEF2, PACSIN1, TRPV4, EVL, AKAP2

GO:0007016

BP

cytoskeletal anchoring at plasma membrane

A cytoskeleton organization process that directly or indirectly links cytoskeletal filaments to the plasma membrane.

FLNB, JUP, EZR, ANK3, DAG1, SPTBN4, EPB41L3, TLN1

GO:0007017

BP

microtubule-based process

Any cellular process that depends upon or alters the microtubule cytoskeleton, that part of the cytoskeleton comprising microtubules and their associated proteins.

TUBB4A, TUBB, NEK3, DYNLL1, TUBA1B, TUBA4A, TUBB4B, TUBB3, DCTN2, TUBA3C, TUBB2A, NEK10, TUBA1A, NEK9, KIFAP3, TUBB6, TUBB2B, EML4, GTSE1, TUBD1

GO:0007018

BP

microtubule-based movement

A microtubule-based process that is mediated by motor proteins and results in the movement of organelles, other microtubules, or other particles along microtubules.

DYNC1LI2, KIF1C, KIF5C, KIF1B, AP2A2, KIF20A, KIF4A, DNAL4, NGF, NTRK1, CLTA, KIF11, AP2S1, AP2B1, CENPE, KIF23, DNAH14, DYNC1I2, DYNC1H1, KIF22, KIF14, DNAH12, KTN1, KIF18B, DNAH10, KIF18A, KIFAP3, AP2M1, KIF20B, KIF2C, SH3GL2, KIFC1, RACGAP1, KIF13B, KIF15, DNAH9, STARD9, KIF3A

GO:0007019

BP

microtubule depolymerization

The removal of tubulin heterodimers from one or both ends of a microtubule.

STMN1, KIF18B, KIF18A, KIF2C, STMN3

GO:0007020

BP

microtubule nucleation

The process in which tubulin alpha-beta heterodimers begin aggregation to form an oligomeric tubulin structure (a microtubule seed). Microtubule nucleation is the initiating step in the formation of a microtubule in the absence of any existing microtubules ('de novo' microtubule formation).

TUBG1, CSNK1D, GOLGA2, TUBGCP3, RANBP9, NDEL1, CENPJ, NDE1, SLAIN2

GO:0007021

BP

tubulin complex assembly

The aggregation and bonding together of alpha- and beta-tubulin to form a tubulin heterodimer.

CRYAB, TCP1, TBCD

GO:0007023

BP

post-chaperonin tubulin folding pathway

Completion of folding of alpha- and beta-tubulin; takes place subsequent to chaperonin-mediated partial folding; mediated by a complex of folding cofactors.

TBCD

GO:0007026

BP

negative regulation of microtubule depolymerization

Any process that stops, prevents, or reduces the frequency, rate or extent of microtubule depolymerization; prevention of depolymerization of a microtubule can result from binding by 'capping' at the plus end (e.g. by interaction with another cellular protein of structure) or by exposing microtubules to a stabilizing drug such as taxol.

MID1, APC, CKAP2, FGF13, ARHGEF2, CIB1, KATNB1, MID1IP1, HDAC6, HDGFRP3